Efficacy and Safety of Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) Over 52 Weeks

被引：0
|
作者：
Yale, Jean-Francois
Bakris, George
Cariou, Bertrand
Iglesias, Javier Nieto
Wajs, Ewa
Figueroa, Katherine
Jiang, Joel
Usiskin, Keith
Meininger, Gary
机构：
来源：
DIABETES | 2013年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1075-P
引用
收藏
页码：A277 / A278
页数：2
相关论文
共 50 条
  • [31] Effect of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) Who Were, or Were Not, on Antihyperglycemic Agents (AHAs) at Screening
    Gonzalez-Galvez, Guillermo
    Kim, Kyoung-Ah
    Jodar, Esteban
    Alba, Maria
    Tong, Cindy
    Meininger, Gary
    [J]. DIABETES, 2014, 63 : A280 - A280
  • [32] Effect of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) Based on Age and Estimated Glomerular Filtration Rate (eGFR)
    Gilbert, Richard E.
    Weir, Matthew R.
    Fioretto, Paola
    Law, Gordon
    Usiskin, Keith
    Meininger, Gary
    [J]. DIABETES, 2014, 63 : A267 - A267
  • [33] BAYESIAN NETWORK META-ANALYSIS (NMA) TO ASSESS THE RELATIVE EFFICACY OF CANAGLIFLOZIN MONOTHERAPY OVER 26 WEEKS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Schroeder, M.
    Taieb, V
    Belhadi, D.
    Seyla-Hammer, C.
    Hemels, M.
    Nielsen, A. T.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A56 - A56
  • [34] EFFICACY AND SAFETY OF TREATMENTS OF TYPE 2 DIABETES MELLITUS (T2DM): A SYSTEMATIC REVIEW (SLR)
    Pettre, S.
    Selya-Hammer, C.
    Ho, S.
    Garg, M.
    Schroeder, M.
    Kaur, V
    Hemels, M.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A433 - A433
  • [35] LIPIDAEMIC PROFILE AND HEART RATE VARIABILITY (HRV) IN CHRONIC KIDNEY DISEASE (CKD) PATIENTS WITH OR WITHOUT TYPE2 DIABETES MELLITUS (T2DM)
    Mylonopoulou, M.
    Antonopoulos, S.
    Mikros, S.
    Katsaros, K.
    Papadakis, G.
    Melidonis, A.
    Tentolouris, N.
    Katsilambros, N.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 237 - 238
  • [36] Canagliflozin review - safety and efficacy profile in patients with T2DM
    Jakher, Haroon
    Chang, Tara I.
    Tan, Marilyn
    Mahaffey, Kenneth W.
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 209 - 215
  • [37] NETWORK META-ANALYSIS TO ASSESS THE RELATIVE EFFICACY OF EMPAGLIFLOZIN MONOTHERAPY OVER 24, 52, AND 76 WEEKS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Daacke, I
    Batson, S.
    Burton, H. E.
    Tebboth, A.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A667 - A667
  • [38] Efficacy and Safety of Ertugliflozin in Hispanic/Latino Patients (Pts) with Type 2 Diabetes Mellitus (T2DM)
    Liu, Jie
    Tarasenko, Lisa
    Ellison, Misoo C.
    Pong, Annpey
    Huyck, Susan
    Mancuso, James P.
    Terra, Steven G.
    Gantz, Ira
    [J]. DIABETES, 2019, 68
  • [39] Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus (T2DM) and Concomitant Heart Failure
    Kosiborod, Mikhail
    Gause-Nilsson, Ingrid Ami
    Sonesson, Christian
    Sugg, Jennifer E.
    Johnsson, Eva
    [J]. DIABETES, 2015, 64 : A313 - A313
  • [40] Efficacy and Safety of Ertugliflozin across Racial Groups in Patients with Type 2 Diabetes Mellitus (T2DM)
    Liu, Jie
    Tarasenko, Lisa
    Pong, Annpey
    Huyck, Susan
    Wu, Larry
    Mancuso, James P.
    Terra, Steven
    Lauring, Brett
    [J]. DIABETES, 2018, 67
12345